Literature DB >> 8462114

TNF production and hypertrophic scarring.

C Castagnoli1, M Stella, C Berthod, G Magliacani, P M Richiardi.   

Abstract

The percentage of TNF alpha- and beta-positive cells was analyzed in hypertrophic scar (N = 13), normotrophic scar (N = 7), and normal skin (N = 6) biopsies using monoclonal antibodies and immunoperoxidase staining of cryostat tissue sections. Samples were first characterized for infiltrating cells. In hypertrophic samples there was a significant increase in activated infiltrating cells, capable of producing TNF beta and IL-1 beta. In contrast, the percentage of TNF alpha-positive cells was significantly lower than that detected in normotrophic scars. In fact, in hypertrophic scar samples a positive staining with anti-TNF alpha mAb was restricted to 8% of tissue-infiltrating cells compared to 35.4% of the cells present in normotrophic scars; 12% of infiltrating cells were stained in normal skin sections. These results suggest that TNF alpha may be important for normal wound healing and that hypertrophic scarring might be partially a consequence of a low amount of TNF alpha.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8462114     DOI: 10.1006/cimm.1993.1047

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  10 in total

1.  Intramuscular hypertrophic scar: an unusual complication following soft tissue sarcoma resection.

Authors:  J X O'Connell; J C English; C P Beauchamp; D G Connell
Journal:  Skeletal Radiol       Date:  1995-05       Impact factor: 2.199

2.  Tumor necrosis factor-alpha mediates diabetes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing.

Authors:  Rongkun Liu; Harbinder S Bal; Tesfahun Desta; Yugal Behl; Dana T Graves
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

3.  Increased release of tumour necrosis factor-alpha in human tear fluid after excimer laser induced corneal wound.

Authors:  M Vesaluoma; A M Teppo; C Grönhagen-Riska; T Tervo
Journal:  Br J Ophthalmol       Date:  1997-02       Impact factor: 4.638

4.  The effect of matrix metalloproteinase 2 and matrix metalloproteinase 2/9 deletion in experimental post-thrombotic vein wall remodeling.

Authors:  Kristopher B Deatrick; Catherine E Luke; Megan A Elfline; Vikram Sood; Joseph Baldwin; Gilbert R Upchurch; Farouc A Jaffer; Thomas W Wakefield; Peter K Henke
Journal:  J Vasc Surg       Date:  2013-03-13       Impact factor: 4.268

5.  Tumor necrosis factor-alpha inhibits collagen synthesis in human and rat granulation tissue fibroblasts.

Authors:  K T Rapala; M O Vähä-Kreula; J J Heino; E I Vuorio; M K Laato
Journal:  Experientia       Date:  1996-01-16

Review 6.  Biology of TNFalpha and IL-10, and their imbalance in heart failure.

Authors:  Kuljeet Kaur; Sanjiv Dhingra; Jan Slezak; Anita K Sharma; Anju Bajaj; Pawan K Singal
Journal:  Heart Fail Rev       Date:  2008-08-19       Impact factor: 4.214

7.  Mast cell chymase promotes hypertrophic scar fibroblast proliferation and collagen synthesis by activating TGF-β1/Smads signaling pathway.

Authors:  Hongming Chen; Yanwen Xu; Guanbin Yang; Qianqian Zhang; Xun Huang; Liming Yu; Xianglin Dong
Journal:  Exp Ther Med       Date:  2017-08-31       Impact factor: 2.447

8.  Importance of monocytes/macrophages and fibroblasts for healing of micronecroses in porcine myocardium.

Authors:  D Weihrauch; M Arras; R Zimmermann; J Schaper
Journal:  Mol Cell Biochem       Date:  1995 Jun 7-21       Impact factor: 3.396

9.  Cicatricial Fibromatosis Causing Cervical Myelopathy Due to Rapid Growth after Removal of Meningioma: A Case Report.

Authors:  Shunsuke Kanbara; Kei Ando; Kazuyoshi Kobayashi; Hiroaki Nakashima; Masaaki Machino; Sadayuki Ito; Taro Inoue; Hidetoshi Yamaguchi; Hiroyuki Koshimizu; Naoki Segi; Shiro Imagama
Journal:  Spine Surg Relat Res       Date:  2021-04-28

Review 10.  The molecular basis of hypertrophic scars.

Authors:  Zhensen Zhu; Jie Ding; Edward E Tredget
Journal:  Burns Trauma       Date:  2016-01-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.